gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BGLCHealthcareMedical Labs

BioNexus Gene Lab Corp Common stock (BGLC)

$0.9500−5.43%
Close Nov 3, 2026 · split-adjusted
Oct 30, 2026$0.89▼ 82.62% in range
Oct 29, 2025Low $0.89 · High $5.48Oct 30, 2026
What changed · written from our data
As of Nov 3, 2026

BioNexus Gene Lab closed at $0.95 on Nov 3, down 5.43%, 82.7% below its 52-week closing high. Volume of 10.7K shares was 1.30× its 20-day average (above normal).

Split-adjusted performance: -25.8% over one month, -53.4% over six months.

In the quarter ended Jun 30, 2026, revenue was $76.16K, down 96.6% from a year earlier, with a net margin of -376.1%.

Short interest was 9.1K shares at the Oct 15 settlement, down 10.5% from the prior report (0.5% of float, 1.0 days to cover).

Market cap$2.8M2.9M shares
Revenue · quarter$76.2K−96.6% YoY
Diluted EPS$-0.12—
P/E · TTM—P/S 0.9×
Net margin-376.1%Gross 17.0%
Dividend yieldNone
52-week range0.92 – 5.48−82.7% from high
Volume10.7K1.30× 20-day avg
Volatility · 60d68.3%Annualised
Short % of float0.5%1.0 days to cover
Net cash$1.2MCash $1.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −15.9%1M −25.8%3M −38.3%6M −53.4%YTD −75.9%1Y —3Y −76.7%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Medical Labs

Percentile among 24 companies (100 = best)

6-month momentum5
Revenue growth0
Net margin10
Value (low P/E)—
Size0

Industry medians: 6-month return +38.2%, revenue growth +25.0%, net margin −4.0%, P/E 32.0×.

Short interest

Details →
Shares short9.1K−10.5% vs prior
Days to cover1.0Settled Oct 15
% of float0.5%
Short vol. 10d31.1%of daily volume

Closest peers by size in Medical Labs

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BGLCBioNexus Gene Lab$0.9500−5.43%−53.4%−96.6%−376.1%—$2.8M
ADVBAdvanced Biomed$2.20+6.02%−67.9%—544.5%0.5$3.6MCompare
ACONAclarion$1.76−2.22%−45.0%+30.5%−10899.5%—$5.1MCompare
AMSAmerican Shared Hospital Services$1.23−1.60%−29.7%+19.2%−6.1%—$8.2MCompare
SERASera Prognostics$1.93−3.02%+2.7%+76.5%−30463.3%—$76.1MCompare
XGNExagen$8.34−0.60%+169.9%+15.9%−16.0%—$202.0MCompare
BDSXBiodesix$21.05−3.35%+40.9%+34.2%−27.1%—$222.1MCompare
FLGTFulgent Genetics$19.37+0.41%+30.0%+4.4%−34.6%—$533.0MCompare
CSTLCastle Biosciences$35.14+0.57%+42.8%+20.1%−2.0%—$1.07BCompare

News about BioNexus Gene Lab

All news →
RYET to Enter Malaysian Healthcare Through Exclusive Cogni AI License to BioNexus Gene LabGlobeNewswire Inc. · Oct 5, 2026▲ Positive

Quick answers

What does BioNexus Gene Lab do?
BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd.
What is BGLC's market cap?
$2.79M, based on the Nov 3 close of $0.95.
Does BioNexus Gene Lab pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BGLC is sold short?
9.1K shares, 0.5% of float, as of Oct 15, 2026.
What sector is BGLC in?
Healthcare, in the Medical Labs industry.

About BioNexus Gene Lab

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

HQ: Kuala Lumpur, 1 employeesListed Mar 11, 2020bionexusgenelab.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology